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Introduction
It is widely accepted that technological change is one of the most important drivers of healthcare spending growth (Fuchs, 1996) . Newhouse (1992) suggests that in the five decades preceding 1990, 50% of US healthcare growth was attributable to new technologies. Barros (1998) suggests that technological change may explain 30% of healthcare expenditure increases in OECD countries. Despite this, research measuring the influence of technology on rising healthcare costs is scarce (Okunade and Murthy, 2002; McGuire and Serra-Sastre, 2009 ). Few studies on costs have explicitly introduced technology variables (Chernew and Newhouse, 2012) . Instead the focus is placed on new drugs (Lichtenberg, 2006; Cïvan and Köksal, 2010) perhaps because technological change is difficult to measure accurately.
This study aimed to investigate whether healthcare technology is an important explanatory factor in rising healthcare costs. Our methodological approach was to introduce genuine technology variables. Building on a previous study (Baker et al., 2003) we analyzed healthcare technology implementation and use by analyzing the availability of medical technologies, which are potentially important cost drivers as they are costly to implement and/or are used to treat patients with expensive conditions. More specifically, we examined the effects of infrastructure-intensive facilities associated with cardiac patient treatment (Percutaneous Transluminal Coronary Angioplasty -PTCA; Pacemaker) and diagnostic imaging (Computed Tomography -CT; Positron Emission Tomography -PET). We considered that digital imaging technology is a good proxy for health technology progress for the following reasons: digital imaging technology is pervasive to several medical fields, is likely to complement new non-imaging technologies and treatments (including drugs), is used intensively in the most expensive therapeutic areas (Dunn et al., 2012) (oncology, cardiology, neurology and orthopedics) and represents the fastest growing part of medical expenditures in the US .
Our research differs from previous work in three major ways. First, we assessed the impact of technology availability on per capita healthcare costs 1 while controlling for the endogeneity of technology variables by investigating the factors associated with technology availability.
Results suggest that medical research, patent intensity and employee density in the medical device industry are influential factors in technology adoption and can be used as instruments for technology availability variables in the cost equation. Second, we relied on a unique exhaustive Swiss dataset of available radiology devices, including devices operated in public hospitals, private hospitals and private practices. In contrast, most US studies are based on the number of hospitals and other locations (e.g. private practices or specialized clinics) reporting to have at least one of these devices, rather than the total number of devices used. Furthermore, our data cover a much longer time span than previous research. Results suggest that previous studies underestimated the magnitude of the relationship between technology availability and healthcare costs, and that this relationship is not the same across technologies.
Whereas increased availability of CT and PET scanners is associated with increased healthcare costs, the opposite is observed for PTCA facilities.
Our research represents a significant contribution both to the literature assessing the impact of technology on healthcare expenditures and to that identifying the determinants of health technology adoption. This paper is structured as follows: Section 2 surveys the economic literature on the impact of medical technology on healthcare costs. Section 3 reviews previous work studying the factors 1 As explained below, healthcare costs considered in this article are utilization costs reimbursed by basic health insurance, plus out-of-pocket expenditures in basic health insurance associated with the diffusion of medical technologies. Section 4 presents data and methods, while Section 5 provides and discusses empirical results. A final section concludes.
The impact of technology on costs: literature background
The main theoretical mechanisms to date are described before outlining the empirical methods generally used to measure the impact of technologies on costs.
Theoretical mechanisms
The literature describes several mechanisms underlying the positive impact of technological change on healthcare expenditures. Two model types exist, one considering technological progress as exogenous, the other endogenous (Chernew and Newhouse, 2012 ).
The first model type investigates how market equilibrium changes as new technology is introduced. Technological progress may have supply-side effects (shifting the technology supply curve to the right or left, depending on whether the new technology engenders higher or lower unit costs) and demand-side effects. The latter reflects a "treatment expansion effect"
whereby new technologies lead more people to be treated for disease (Cutler and McClellan, 2001 ). This may help explain how new healthcare technology with lower unit costs sometimes results in higher total healthcare expenditures (Cutler and Huckman, 2003) . The other model type focusses on the process of technical innovation, in particular, modeling the relationship between technology change and medical expenditures through healthcare insurance (Weisbrod, 1991; Feldstein, 1977; Chandra and Skinner, 2012 by-product of the interaction between innovation and insurance.
Empirical studies
Residual estimates and technology proxies serve as measures of technological change when empirically assessing its impact on healthcare expenditures.
The residual estimates approach assesses the impact of easily observable cost drivers, including income per capita, population age distribution, physician density and extent of insurance coverage 2 on health care costs. It then attributes the portion of healthcare spending not accounted for to healthcare technology (Newhouse, 1992; Barros, 1998) . One drawback with this approach is that the impact of technology may be overestimated if other factors are incorrectly specified.
To date, various proxies have been used in the technology proxies approach. Some studies have used insurance coverage as a proxy for medical technology (Peden and Freeland, 1998) .
Others have incorporated a linear time trend (Blomqvist and Carter, 1997 ) since technological change occurs over time. However, a trend variable may capture effects of various nonstationary variables, and its incorporation severely affects the parameter estimates of other explanatory variables, in particular income (Roberts, 1999) . Furthermore, the linear nature may be inappropriate if medical technology innovation is not linear (Willemé and Dumont, 2014) . Still other studies have used R&D spending specific to healthcare (Okunade and Murthy, 2002) or non-commercial medical research (Peden and Freeland, 1995) . One problem with this proxy type is that it approximates innovation inputs but not innovation diffusion (Kleinknecht et al., 2002) .
In order to alleviate such shortcomings, a fourth set of proxy-based studies in the literature have used explicit measures of medical equipment, such as the percentage of hospitals with high-tech equipment or the availability of infrastructure-intensive facilities. These studies have reported a positive impact on total costs for PET scanners (Koenig et al., 2003; Baker et al., 2003) , CT scanners (Baker et al., 2003; Baker et al, 2008) , Magnetic Resonance Imaging (MRI) (Koenig et al., 2003 , Baker et al., 2008 , implantable cardioverter defibrillator facilities (Baker et al., 2003) and neonatal intensive care units (NICUs) (Baker et al., 2003) , and a negative impact on costs for PTCA (Baker et al., 2003; Hearle et al., 2003) . Non-significant results or inconsistent results have been found for single-photon emission computed tomography scanners (SPECT) (Koenig et al., 2003; Hearle et al., 2003) and radioisotope services (Hay et al, 2003; Hearle et al., 2003) . 
The characteristics of adopters (demand for medical technologies)
Demand for medical technologies is driven by providers (physicians) and consumers (patients).
For providers, the adoption of new technologies is influenced by informed and influential individuals (Huckman and Pisano, 2006; Aarons et al., 2011) . Adoption has been shown to depend on the positive influence of specialist physicians (Baker, 2001 (Spangenberg et al., 1990; Escarce, 1996; Bobrowski, 2000; Cutler and Kadiyala, 2003; Estabrooks et al., 2008; Angst et al., 2010) . Second, as well as being adopters, researchers are producers of knowledge likely to be shared with device suppliers in order to convert their ideas into innovations. These specific technology users are thus kept up to date and even mollycoddled by device suppliers (Von Hippel and Finkelstein, 1979; Rosenberg, 1992; Riggs and Von Hippel, 1994; Heidenreich and McClellan, 2003; Lettl et al., 2006 ; Hyysalo, 2006 ; Chatterji et al., 2008) . Finally, researchers have lower adoption costs because they are more accustomed to exploring and absorbing new technologies (Cohen and Levinthal, 1989; Åstebro, 2004) .
With respect to patients, previous research has highlighted the role of income and education in the diffusion of new technologies. GDP per capita is a major driver of the early adoption of medical technologies (Slade and Anderson, 2001 ). This has also been found at the micro level but with more mixed results (Cutler and McClellan, 1996; Baker, 2001) . Other research has highlighted that people with higher educational levels are more likely to be aware of recent innovation in medical imaging devices and have easier access to related procedures (Lleras-Muney and Lichtenberg, 2002) .
The supply of medical technologies
With respect to the device industry, the presence of a local high-tech industry is considered influential in the adoption and diffusion of technologies. The adoption and performance of novel technologies usually involves important complementary assets (Teece, 1986; Milgrom and Roberts, 1990 ) such as high-tech equipment or intermediary goods and services. These include skilled employees (Barley, 1986; Schumacher, 2002; Dranove et al., 2012) 
Financing and geographic environments
Regarding healthcare financing, numerous empirical studies highlight faster adoption of new technologies in areas where insurance coverage is higher (Russell, 1979; Cutler and Sheiner, 1998) . There is also evidence that a reduction in financial incentives for healthcare providers may slow the adoption of new technologies. For example, prospective payment systems (PPS) in hospital financing have been shown to delay the diffusion of cost-increasing technologies (Romeo et al., 1984) . This is also true for MRI in HMO (Health Maintenance Organizations) programs in the American system (Baker, 2001) , for angioplasty (Cutler and McClellan, 1996) and NICUs (Baker et al., 2002) . However, other studies did not find any relationship between the HMO market share and technology diffusion (Hill and Wolfe, 1997) .
Finally, geographic distance between healthcare providers can accelerate or hamper adoption strategies among healthcare units competing in the same health market. Acceleration arises from competition with already-equipped neighbors (competition behavior), while delays occur if patients can be transferred to already-equipped neighbors (cooperation behavior) (Cutler and McClellan, 1996) .
Although the role of researchers and the existence of a local high-tech medical industry are common factors in the study of economics of innovation dealing with technology adoption in several fields, the present study is the first to test whether they are possible determinants of innovation adoption in the medical device sector. We also investigated whether these two variables could serve as instruments for technology availability in the healthcare cost equation. We expected them to have a direct impact on the adoption of new technology and an indirect impact on costs -through the availability of costly technology -as there is no reason why they should have a direct impact on expenditures reimbursed by basic insurance 3 .
Methods and data
We studied the impact of technology availability on costs, and the factors associated with healthcare technology availability. We built a longitudinal dataset for Switzerland 4 using the period 1996-2007, information being reported at two levels: canton (c) and year (t). Our database comprised 312 observations. Tables 1 and 2 describe all variables and sources.
We modelled per capita expenditures on healthcare services (denoted C ct ) as follows:
C ct included services covered by compulsory basic health insurance for adults over 25 5 . The other main sources of healthcare financing included expenses covered by voluntary supplementary health insurance (9.2%), household direct contributions (25%) through out-of-pocket payments for healthcare goods not included in the basic or supplementary benefit packages, and public subsidies to local facilities (16.2%). The first two sources of healthcare financing were not considered for data availability reasons, the latter because it is not a good measure of healthcare costs generated by citizens. In particular, public subsidies include expenditure for prevention as well as support for research and teaching activities. Note that it is crucial not to consider this latter type of cost for the relevance of our proposed instruments. 6 MRI was not included in the set of variables because information on MRI availability was not collected in medical practice settings by federal authorities. Note that 96.4% of hospital centers which were equipped with MRI were also equipped with CT scanners (source: authors' computations on Swiss hospital key figures published by Federal Office of Public Health, 2003 Health, -2012 . Further research may consider to build an index of technology based on imaging devices. 7 Switzerland progressively implemented a Diagnostic Related Group (DRG) payment system between 2002 and 2012 Canton-fixed effects (c c ) captured unobserved heterogeneity between cantons (e.g. cultural factors, inclination to use healthcare).
A canton fixed-effects linear model was estimated, thus controlling for the panel structure of the data. A key econometric issue is that the coefficient β 1 is likely to be biased if technology variables are endogenous.
Davidson-MacKinnon exogeneity tests were performed. The possible endogeneity of T ct variables was accounted for using an Instrument Variable (IV) approach. When the four technologies were introduced together in (1), at least four instruments were needed. To identify potential instruments (i.e. variables that are correlated with technology densities but which have no direct effect on healthcare costs and are thus excluded from the cost equation) for the technology density variables, we estimated a Tobit model based on the density of each technology. A Tobit model seemed the natural solution to account for the censored nature of our data. Zero values for technology density in a small number of cantons did not mean those cantons had zero willingness to pay for installations of technologies, but that their willingness to pay was lower than an "adoption threshold" (not observed). Thus, estimations were based on the latent variables * ct T :
A ct is a vector of adopter's characteristics variables. In addition to the demand and supply variables described above, certain variables were specific to the technology adoption equations. The role of research was estimated using the density of medical publications computed for the four most costly medical fields (cardiology, oncology, neurology, orthopedics) (Dunn et al., 2012) and for radiology (Appendix 2). These are the research fields most likely to influence the adoption of the four technologies under investigation.
Regarding the characteristics of medical device companies included in MD ct , the presence of a local high tech industry was captured using locally experienced human resources (employee density in the medical device industry) and inventive capabilities (patent intensity) (Appendix 2).
FG ct refers to financing and geographic variables. To capture potential spatial interactions, we computed a weighted index of devices installed in other cantons (Appendix 2). Regarding the financing environment, we used the insurance variables described above.
Research, skilled human resources, patent densities and neighbour variables were lagged in the regressions to mitigate potential endogeneity problems.
We formally tested the validity of our potential instruments. Three tests were performed.
First, in order to rule out any direct effect of the potential instruments on the cost variable, we ran the cost equation (1) including potential instruments as covariates. Second, we performed a Sargan test in order to test the assumption that instruments were uncorrelated with ct  .
Third, in order to test for the strength of our instruments, we computed from the first-stage regressions (i.e. equations 2) F-statistics of a joint test whether all excluded instruments were significant (Staiger and Stock, 1997) . Table 3 for the meaning of abbreviations of Swiss cantons 9 Note that CT scanner adoption is reversible. Some hospitals and medical practices were equipped at some point but were no longer equipped a couple of years later. equipped with PTCA facilities. A mixed pattern was also found for pacemakers, with high densities in cantons with high (e.g. JU, NE) and low (e.g. UR, AR) healthcare expenditures. exhibited the highest densities of employees working in the medical device industry.
Results

Descriptive results
The determinants of technology adoption
As the equations studying factors associated with technology diffusion aim to identify potential instruments for technology density, we will first comment on the analyses of the determinants of technology adoption. The econometric results are displayed in Table 4 (CT and PET scanner densities) and Areas with a higher proportion of HMO subscribers were associated with a higher density of PTCA and pacemaker facilities. This can be interpreted in the light of the results on costs (see next section). HMOs boosted the introduction of equipment which reduces costs (PTCA). In this respect, HMOs may be expected to reduce healthcare costs.
A higher percentage of insurance policyholders with high deductibles was not significantly associated with the diffusion of technologies. Unlike other studies, we did not find that the higher the extent of insurance coverage the higher the density in technology (Russell, 1979) .
This may be explained by the fact that the Swiss population benefits from wide insurance coverage in all plans, including those with the highest deductibles.
The DRG payment variable was not associated with any technology densities and was therefore dropped from regressions. This may be because our dataset does not cover the full period during which DRG payment system was implemented. Furthermore, a Sargan test led to the non-rejection of the null hypothesis that these instruments are uncorrelated with ct  (p = 0.810) 12 . Furthermore, F-statistics from the first stage regressions show that F > 10 (columns 2-5 in Table 6 ), suggesting that our instruments meet Staiger and Stock's (1997) strong instrument criteria. Altogether these results suggest that our instruments are valid.
10 NEIGHBOR is more a control variable and will technically serve as an instrument 11 Joint test that all coefficients are zero 12 The Sargan Test was performed on specification 6 ( Table 6 ). This result is important because it rules out the possibility that our instruments could have been correlated with technologies not captured by our technology variables (e.g. availability of certain drug technologies). One important result is that the magnitude of the relationship between technology availability and healthcare costs was much stronger when we controlled for the endogeneity of the availability of technologies (columns 2-6). The Davidson-MacKinnon's tests reported in Table   6 rejected the null hypothesis that technology variables were exogenous. We found that the magnitude of the coefficients for PET and CT scanners was twice as big when controlling for the endogeneity of the technology variable (comparing column 6 with column 1). importance of medical research as a driver for technology adoption also suggests that costly medical devices are not only adopted for treatment reasons but may be installed for medical research. This creates another source of benefit associated with new technologies. However, intensive medical research and the presence of a medical high-tech industry do not systematically lead to increased healthcare costs (e.g. pacemakers and PTCA).
The impact of technology on costs
With respect to other control variables in the cost equation, a higher income level was not significantly associated with higher healthcare expenditures. This result is consistent with others on Swiss data (Crivelli et al., 2006) . Neither was a higher unemployment rate associated with healthcare expenditures. In contrast, a higher density of specialist physicians was associated with higher healthcare costs. This is not surprising in a fee-for-service system and may suggest a potential supply-induced demand problem (Crivelli et al, 2006; Reich et al., 2012) . A higher percentage of elderly people in the Swiss population was not significantly associated with healthcare costs, although it did have an indirect impact through the availability of devices (positive for CT and PET density, negative for PTCA density). A higher percentage of less-educated people was associated with reduced healthcare costs. The percentage of enrollees with high deductible health plans was not significantly associated with healthcare costs. This suggests that the introduction of deductibles in Switzerland did not help solve the moral hazard problem (Schellhorn, 2001) . Areas with a higher percentage of enrollees in HMO-type plans had lower healthcare expenditures. This is consistent with Reich et al. (2012) . The DRG variable was not significant and was dropped from regressions.
Conclusion
Our study investigated the direction and magnitude of the relationship between selected technologies and healthcare costs and is, to our knowledge, the first to control for the possible endogeneity of technological availability. Our results suggest that increased availability of CT and PET devices is associated with increased healthcare costs. The opposite relationship is observed for PTCA facilities. This is consistent with studies which, unlike ours, did not account for the endogeneity of the supply of technologies. However, the magnitude of these relationships in our study is much bigger in absolute value. We show that the bias associated with endogeneity is substantial and thus strongly reduces the actual impact of technology on costs. Our results highlight that medical research, patent intensity and the local availability of a skilled labor force working in the medical device industry facilitate the adoption of medical technology and can be used as valid instruments for technology availability in the cost equation. In this respect, our work contributes significantly both to the literature assessing the impact of technology on healthcare expenditures, and to that identifying the determinants of health technology adoption, shedding light on the mechanism through which certain geographic areas are more equipped in expensive technologies than others and thus may exhibit higher health care costs.
Although a selected number of technologies can only partially capture the overall level of technology availability in a geographic area, our paper is an important contribution to the literature, given that it is one of the first to look at the relationship between technological change and health care costs outside the US. Furthermore, the proposed methodology to account for the possible endogeneity of technology availability can be easily applied to the understanding of health care costs variability within any given country or between two or more countries, as publicly available datasets, PATSTAT and SCOPUS, were used to compute patent intensity and research intensity , respectively.
Overall, our results question whether it is appropriate to point the finger at those cantons with higher healthcare costs. Since expensive cantons may also be the ones with intensive medical research, they are the cantons contributing most to future treatments which in time will become available to all cantons. In this respect, these results remind us of the necessity to assess the benefits associated with new medical technologies in a global and dynamic fashion.
Appendix 1: The Swiss health insurance system
Switzerland (population 7.8 million in 2009) is divided into 26 geographic areas (cantons), with each canton responsible for the organization of its own healthcare system. The basic health insurance system is regulated by the Federal Law on Social Health Insurance (LAMal).
Basic health insurance is obligatory in Switzerland and a standardized benefit package is defined by law. However the extent of coverage varies as policyholders may choose between contracts with a low deductible level ( 
Cost-sharing arrangements in basic insurance
All contracts include a deductible on yearly expenditures. Once the deductible level has been reached, enrollees pay a 10% co-insurance rate up to a maximum of 700 CHF. Hence, if the enrollee chooses a 300 CHF deductible, then the maximum out-of-pocket amount that he or she may have to pay is 1000 CHF.
Appendix 2: Computation methods for the number of publications, employees working in the medical device industry, patents and for spatial interactions
Number of publications
We computed the annual number of publications in medical fields including at least one author with a Swiss affiliation. Only publications of articles, editorials and letters in journals listed in Scopus over 1995-2006 were taken into account. The cantonal count was weighted and computed as the number of authors affiliated in a given canton divided by the number of authors affiliated with Swiss institutions. For example, an article with 2 authors from a Bern institute, 1 author from a Geneva institute and 2 non-Swiss authors associated with 2 non-Swiss institutes will lead us to credit the Bern and Geneva Cantons respectively of 2/3 and 1/3 publications. Similarly, we computed the number of academic publications in five specific medical fields (cardiology, oncology, neurology, radiology, orthopedics)
Number of employees working in the medical device industry
The total number of employees working in the medical device industry was computed, using the ISIC classification (NOGA in Switzerland) at the three digit level, as the sum of employees in two industries, the ISIC 266 industry that is the manufacture of irradiation, electromedical and electrotherapeutic equipments, and the ISIC 325 industry which is the manufacture of medical and dental instruments and supplies. Hospitals and medical laboratories can find skilled technicians in these two industries. The number of employees in these industries were available only for 1995, 2001, 2005 and 2008. The annual values were approximated taking the nearest year into consideration.
Number of patents
The patents considered in this study are those including applicants or inventors who provided an address in Switzerland and belonged to the A61B subclass in the IPC classification filed between 1992 and 2006. This IPC subclass covers instruments, implements, and processes for diagnostic, surgical and person-identification purposes, including obstetrics, instruments for cutting corns, vaccination instruments, finger-printing and psycho-physical tests. The year considered for invention is the earliest priority date (filing). The number of patents was calculated at the canton level according to the NUTS3 classification taken from the REGPAT database (OECD, 2008) .
Spatial interactions
Following Shroder (1995) and Figlio et al. (1999) , we used the inter-canton hospital patient mobility data in order to weight the competing offers of other cantons where patients can be treated 14 . The weight is the fraction of patients who went to (an)other canton(s) to be treated: canton i assigns each other canton j a weight of ∑ where is the number of patients of canton i going to be cured in canton j. is thus the share of patient of canton i that is treated in canton j out of the total number of patients treated outside canton i, in one of the other 25 cantons. Canton i is assigned a weight of zero ( 14 Insured people may choose to be treated at any hospital or at any physician's practice and therefore may be treated in cantons other than the one where they live. However, there are restrictions on reimbursement by basic insurance for inpatient care received outside the canton of residence or for outpatient care received outside the canton where policyholders live or work. An individual will be reimbursed only up to the amount that would have been charged in his/her canton of residence. If it is imperative to receive outpatient care outside the canton in which the individual lives or works, e.g. in an emergency or because he/she requires special treatment, health insurance will cover all the costs. ), and all weights sum to 1. The weight is then multiplied by the technology density in each canton, to provide a composite indicator of neighboring competitors in each technology for each canton i. For example, for CT scanners, for each canton i we generated the variable ∑ . The NEIGHBOUR variable was computed in a similar way for the three other technologies.
(1)
(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) GLS GLS GLS GLS GLS GLS GLS GLS GLS GLS GLS
coef/t coef/t coef/t coef/t coef/t coef/t coef/t coef/t coef/t coef/t coef/t
CTt 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** 0.005*** (7.222) (7.312) (7.523) (7.875) (7.237) (7.157) (7.455) (7.359) (7.687) (7.698) (7.403) PETt 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** 0.011*** PTCAt -0.011** -0.011** -0.011** -0.012** -0.011** -0.011** -0.011** -0.011** -0.011** -0.011** -0.011** EDUCATIONt -0.002** -0.002** -0.002** -0.002** -0.002** -0.002** -0.002** -0.002** -0.002** -0.002** -0.002** (7.713) (7.796) (7.963) (7.462) (7.935) (7.425) (7.517) (7.378) (7.728) (7.893) (7.957) HMOt -0.001** -0.001** -0.001** -0.001** -0.001** -0.001** -0.001** -0.001** -0.001** -0.001** -0.001** ( (1997, 2002, 2007) conducted by the FOS SSC: Swiss Society of Cardiology CDS: Conférence Suisse des directrices et directeurs cantonaux de la santé a based on the full list of federal licenses granted in Switzerland since the introduction of these technologies. b information collected since 1987 in a nationwide annual survey by the working group "interventional cardiology and acute coronary syndrome" (Pedrazzini, 1998; Roffi, 1999; Roffi, 2000; Wahl, 2001; Togni, 2002; Schülter et al, 2004; Maeder et al., 2006; Maeder et al., 2008; Maeder et al., 2010) c information collected by the working group "Arrhythmia and Electrophysiology" since 1992 (http://www.pacemaker.ch) * CTct and PETct were corrected for, using the number of months during which each CT and PET device was actually in operation. This data was available thanks to the availability of installation and withdrawal dates (for withdrawn devices). Combined PET/CT devices ("combos") were included in the number of PET scanners, without any consequence on our results. CT PET *** significant at the 1% level, ** significant at the 5% level, * significant at the 10% level All regressions are Tobit panel data with canton fixed effects and time dummies N = 312 (t=12) a Wald test of H0: the coefficients of the five publication variables are jointly equal to zero: P=0.0015 b Wald test of H0: the coefficients of the five publication variables are jointly equal to zero: P=0.0023 c the variable NEIGHBOUR is specific to each technology (see Appendix 2) EDUCATION t -0.002** -0.002** -0.003** -0.003** -0.002** -0.002** -0.002** SPECIALIST t 0.128*** 0.110*** 0.121*** 0.144*** 0.109*** 0.125*** 0.125*** (7.713) (7.887) (7.999) (8.810) (7.967) (6.897) (6.133) HMO t -0.001** -0.002** -0.002** -0.002** -0.003** -0.011** -0.002** (-2.219) (- Figure 1 : Level (2007) and evolution (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) of monthly per capita healthcare expenditures for adults older than 25, by canton 
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